Background: Recently, platelet-rich plasma (PRP) injection has been proposed as a
| INTRODUCTION
Androgenetic alopecia (AGA) is the most common form of noncicatricial alopecia, affecting up to 80% of men and 50% of women in the course of their life. Hair thinning results from the effects of testosterone metabolite dehydrotestosterone (DHT) on androgensensitive hair follicles. However, genetic predisposition is very important to better determine the onset, the severity, and the pattern of the disease. The hair follicles of selected areas of the scalp undergo a gradual transformation (miniaturization), which causes reduction in size due to a shorter anagen phase. With each hair cycle, the length of anagen is progressively reduced, while the length of telogen remains constant. In women, AGA produces diffuse thinning of the crown region with maintenance of the frontal hairline (Ludwig pattern). Severe AGA often involves parietal and occipital regions with diffuse thinning. Today, diagnosis is based on clinical examination and scalp dermoscopy, permitting differential diagnosis with other diseases, staging of severity, and monitoring the evolution over time of the disease. Currently, medical therapies approved by Food and Drug Administration (FDA) for treating AGA are minoxidil and finasteride, 1 alone or in combination. Their use is different between the sexes: In particular, in female AGA, the best choice is 2% minoxidil lotion, applied twice a day, and in selected cases, oral antiandrogens can be used. The treatment must be continued for long periods, to maintain improvement: In fact with the withdrawal of every treatment, there is an immediate progression of the disease. Recently, platelet-rich plasma (PRP) injection has been proposed as a potential adjuvant therapeutic technique for androgenetic alopecia.
Platelet-rich plasma is an autologous preparation of platelet in concentrated plasma. Although the optimal concentration is not yet entirely clear, the current technique by which PRP is prepared provides 300-700% enrichment (usually more than 1 000 000 platelets/ microl).
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Platelet-rich plasma has begun to be used in many specialties, such as orthopedics, aesthetic, and plastic surgery, because platelet activation promotes wound healing and induces tissue regeneration, with the release of various growth factors and cytokines, such as platelet-derived growth factor, transforming growth factor beta (TGF-b), vascular endothelial growth factor, epidermal growth factor, and insulin-like growth factor.
Recent studies have evaluated the efficacy of PRP during hair transplants, observing a considerable improvement of the density and regrowth of the transplanted hair follicles after the growth factors' stimulation. The hypothesized mechanism is based on a direct action of platelet growth factors of the bulge area, by stimulating the growth of new hair follicles and promoting neovascularization.
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The aim of our study was to evaluate the safety and the efficacy of PRP for treatment of female AGA, with the support of scalp dermoscopy and global photography. Autologous platelet-rich plasma was prepared under laminar flow hood to obtain a sterile final product. In particular, My Cells â system (platelet preparation tube) was used as it is a certified medical device able to collect with a minimal manipulation a highly concentrated and pure amount of autologous platelet-rich plasma (5 mL) starting from a minimum sample of whole blood from the patient (10 mL). The test tube used for blood sampling contained a modified solution of anticoagulant, called acid-citrate-dextrose type (ACDA), in which the physiological pH was reached to preserve the platelet integrity. The experimental protocol requires a first centrifugation of whole blood sample at 2500 rpm for 10 minutes using a tilting rotor centrifuge previously balanced with the control.
| MATERIALS AND METHODS

| Patients
A separation of platelet from red and white blood cells was We used a standardized grid located on the scalp at every session, using as primary reference the Kang's point or "V" point. The 
| Objective and subjective evaluation
The primary objective of the study was to evaluate the efficacy and tolerability of PRP at the end of the treatment (7 days after the last injection), and at the follow-up visits (12 and 24 weeks).
Secondary objectives of the study were to evaluate the clinical improvement by pull test, global photographs, and Trichoscan at weeks 9, 12, and 24.
Hair measurements were performed using FotoFinder dermato- The vellus relative change instead showed a decrease since the beginning for both areas. At the second follow-up visit (after 12 weeks), vellus showed significant reduction and there had been a big reduction, evident especially in the front and the central area (À16.1% and À7.1%, respectively), followed by another significant big reduction at the end of follow-up for the central vellus, while for the vertex, the decrease was mainly visible at the end of the study (À6.6%). The measurements of the medium hair diameter in frontal area showed important increases after 12 weeks (%RD = 12.5, with P-value < .05) and after 24 weeks (%RD = 14.6, P-value < .05). 
| DISCUSSION
Platelet-rich plasma is defined as autologous plasma containing a supraphysiological concentration of platelets. PRP has been studied in dermatology for its possible effects on hair growth since 2012, with a study in vitro and in vivo in mice. 2 Despite its use in many scientific fields, the actual mechanisms of action on hair follicle are still under discussion and it is far from complete. According to Lee et al, 4 in vitro PRP induces the proliferation of dermal papilla cells and prevents the apoptosis by inducing the increase in Akt and Bcl-2's expression. Furthermore, PRP contributes to the formation of hair epithelium and stem cell differentiation into hair follicle cells, thanks to an upregulation of beta catenin, which is expressed in the bulge area of the follicle. 4 The increased expression of FGF-7 (fibroblast growth factor-7) determines an extended anagen phase of hair cycle. Moreover, in androgenetic alopecia, PRP increases proliferation of bulge cells with release of Ki-67. 5 At the end, thanks to the suppression of inflammatory cytokines, PRP appears as a potent anti-inflammatory agent. Based on a review of the literature, only 2 studies in female patients have an evidence-based evaluation. 4, 6 Gkini et al, 4 performing 3 treatment sessions of PRP at 3-week interval with a further treatment after 24 weeks, observed an improvement of hair density of 7.41% compared to baseline at the 1-year control, and the best result was noted after the third session.
At least, they concluded that there is insufficient evidence that PRP therapy can induce an improvement in patients with AGA. Furthermore, Lee et al, 6 shared the same result, in double-blind study with a higher number of female patients affected by androgenetic alopecia, but with a shorter study duration, lasting 12 sessions at weekly intervals. Another important difference between the two authors is the use of additional components, as CD34+ cells, present in the second study. In the literature, the addition of differences in the types of components used is another important point of discussion, 3, 4, 7 suggesting a positive contribution to PRP effect on hair regrowth. In both studies, there is insufficient evidence that PRP therapy is able to induce significant improvement of AGA over time. The results of our study confirmed that the administration of PRP causes a homogenous and significant improvement in mean terminal hair density and hair diameter, and a reduction of vellus hair.
We agree that more controlled and well-designed clinical trials are needed to better understand this innovative technique. In addition, in the literature, there is no consensus protocol on standard method for using PRP: A specific concentration, dosage, depth and site of injections, frequency or number of sessions have never been approved.
First of all, frequency of sessions ranges from two to five treatments, spaced from a week to 12 weeks apart. Therefore, PRP is produced using different methods of centrifugation, cells separation, or combination with other chemicals or cells. Also there is no standard method for evaluation of results among different studies, even if global photography and scalp dermoscopy were the most frequently used.
According to statistical results of our study, we stated that PRP can be defined as a valid method as adjuvant treatment of female androgenetic alopecia, especially in patients refractory to standard approved therapies such as minoxidil and finasteride.
We encourage new clinical studies to standardize the technique.
Important questions remain open: additional components, minimum required frequency of treatments for effective results, and optimal duration of the therapy to maintain the results. Moreover, there is no official protocol, so in the literature, there are different data without standardization, and there is no consensus if PRP has a proved efficacy.
In addition, studies on female AGA are lacking.
PRP appears as a safe alternative option for patients affected by female androgenetic alopecia, but new research is needed to assert in which cases it is really necessary.
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